Newton Biocapital is a venture capital fund that invests in early-stage biotech and deep tech companies, focusing on chronic health conditions. With a presence in Japan and Europe, the fund supports its portfolio through early drug development phases and effective clinical trial design. Investments include Santero Therapeutics and DeuterOncology. Partnering with Newton Biocapital helps grow the biotech sectors in Japan and Europe while positively impacting global health.
